机构：[1]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China[2]Laboratory of Molecular Pharmacology, Department of Pharmacology, School of Pharmacy, Southwest Medical University, Luzhou, China[3]South Sichuan Institute of Translational Medicine, Luzhou, China[4]Department of Oncology and Hematology, Hospital (T.C.M) Affiliated to Southwest Medical University, Luzhou, China[5]School of Chinese Medicine, Hong Kong Baptist University, Hong Kong, China[6]College of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China
The introduction of targeted therapy is the biggest success in the treatment of cancer in the past few decades. However, heterogeneous cancer is characterized by diverse molecular alterations as well as multiple clinical profiles. Specific genetic mutations in cancer therapy targets may increase drug sensitivity, or more frequently result in therapeutic resistance. In the past 3 years, several novel targeted therapies have been approved for cancer treatment, including drugs with new targets (i.e., anti-PD1/PDL1 therapies and CDK4/6 inhibitors), mutation targeting drugs (i.e., the EGFR T790M targeting osimertinib), drugs with multiple targets (i.e., the EGFR/HER2 dual inhibitor neratinib) and drug combinations (i.e., encorafenib/binimetinib and dabrafenib/trametinib). In this perspective, we focus on the most up-to-date knowledge of targeted therapy and describe how genetic mutations influence the sensitivity of targeted therapy, highlighting the challenges faced within this era of precision medicine. Moreover, the strategies that deal with mutation-driven resistance are further discussed. Advances in these areas would allow for more targeted and effective therapeutic options for cancer patients.
基金：
National Natural Science
Foundation of China (Grant nos. 81503093, 81602166, and
81672444) and the Joint Funds of the Southwest Medical
University and Luzhou (2016LZXNYD-T01, 2017LZXNYD-Z05,
and 2017LZXNYD-J09). The funding from National Natural
Science Foundation of China (Grant nos. 81503093) will cover
open access fee.
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2019]版：
大类|3 区医学
小类|3 区肿瘤学
最新[2023]版：
大类|3 区医学
小类|3 区肿瘤学
第一作者：
第一作者机构：[1]Department of Oncology, The Affiliated Hospital of Southwest Medical University, Southwest Medical University, Luzhou, China
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Jin Jing,Wu Xu,Yin Jianhua,et al.Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy.[J].Frontiers in oncology.2019,9:263.doi:10.3389/fonc.2019.00263.
APA：
Jin Jing,Wu Xu,Yin Jianhua,Li Mingxing,Shen Jing...&Qu Liping.(2019).Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy..Frontiers in oncology,9,
MLA：
Jin Jing,et al."Identification of Genetic Mutations in Cancer: Challenge and Opportunity in the New Era of Targeted Therapy.".Frontiers in oncology 9.(2019):263
